Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Red yeast rice is an herbal supplement that decreases low-density lipoprotein (LDL) cholesterol level. OBJECTIVE: To evaluate the effectiveness and tolerability of red yeast rice and therapeutic lifestyle change to treat dyslipidemia in patients who cannot tolerate statin therapy. DESIGN: Randomized, controlled trial. SETTING: Community-based cardiology practice. PATIENTS: 62 patients with dyslipidemia and history of discontinuation of statin therapy due to myalgias. INTERVENTION: Patients were assigned by random allocation software to receive red yeast rice, 1800 mg (31 patients), or placebo (31 patients) twice daily for 24 weeks. All patients were concomitantly enrolled in a 12-week therapeutic lifestyle change program. MEASUREMENTS: Primary outcome was LDL cholesterol level, measured at baseline, week 12, and week 24. Secondary outcomes included total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, liver enzyme, and creatinine phosphokinase (CPK) levels; weight; and Brief Pain Inventory score. RESULTS: In the red yeast rice group, LDL cholesterol decreased by 1.11 mmol/L (43 mg/dL) from baseline at week 12 and by 0.90 mmol/L (35 mg/dL) at week 24. In the placebo group, LDL cholesterol decreased by 0.28 mmol/L (11 mg/dL) at week 12 and by 0.39 mmol/L (15 mg/dL) at week 24. Low-density lipoprotein cholesterol level was significantly lower in the red yeast rice group than in the placebo group at both weeks 12 (P < 0.001) and 24 (P = 0.011). Significant treatment effects were also observed for total cholesterol level at weeks 12 (P < 0.001) and 24 (P = 0.016). Levels of HDL cholesterol, triglyceride, liver enzyme, or CPK; weight loss; and pain severity scores did not significantly differ between groups at either week 12 or week 24. LIMITATION: The study was small, was single-site, was of short duration, and focused on laboratory measures. CONCLUSION: Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Different commercial preparations of RYR have different concentrations of monacolins, the bioactive ingredients, and lower TC and LDL-C, 71 but the long-term safety of the regular consumption of these products is not fully documented.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [71]
In the citing paper
“For all previously mentioned studies, there were no safety concerns (80,126-130).”
From The Role of Nutraceuticals in Statin Intolerant Patients (2018) · cites this paper as [126]
In the citing paper
“RYR has been used as an alternative to statin therapy in treating patients with mild to moderate hypercholesterolemia, particularly in those considered to be statin intolerant, and clinical studies suggest that RYR is well tolerated, safe, and effective for CVD primary prevention (126-128).”
From The Role of Nutraceuticals in Statin Intolerant Patients (2018) · cites this paper as [126]
In the citing paper
“some nutraceuticals are then able to enhance (126,127,135-137,145-147) or potentially replace the action of statins (63-66,50-52,58,168,169).”
From The Role of Nutraceuticals in Statin Intolerant Patients (2018) · cites this paper as [126]
In the citing paper
“Becker et al. (126) showed that the use of RYR significantly reduced LDL-C and TC levels compared with placebo without increasing the incidence of myalgia in 62 dyslipidemic patients who could not tolerate statin therapy (126).”
From The Role of Nutraceuticals in Statin Intolerant Patients (2018) · cites this paper as [126]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Adherence to a Mediterranean diet and survival in a Greek population
Trichopoulou, A., Costacou, T., Bamia, C., & Trichopoulos, D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025039 · Cited by 4,397
de Lorgeril, M., Salen, P., Martin, J.-L., Monjaud, I., Delaye, J., & Mamelle, N. (1999) · Circulation · doi:10.1161/01.cir.99.6.779 · Cited by 2,910
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 1×
“A recent study showed that patients with variants in the SLCO1B1 gene were more likely to develop statin-associated myopathy with higher doses of simvastatin (31).”
BackgroundFletcher, G. F., Balady, G. J., Amsterdam, E. A., Chaitman, B., Eckel, R., Fleg, J., Froelicher, V. F., Leon, A. S., Piña, I. L., Rodney, R., et al. (2001) · Circulation · doi:10.1161/hc3901.095960 · Cited by 1,923 · cited 1×
“It incorporated the Mediterranean diet (33–36), an exercise program, and relaxation techniques, which have been collectively shown to favorably affect serum lipid levels and reduce weight, blood pressure, and mortality (37, 38).”
MethodDansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005) · JAMA · doi:10.1001/jama.293.1.43 · Cited by 1,726
Effects of the amount and intensity of exercise on plasma lipoproteins
Kraus, W. E., Houmard, J. A., Duscha, B. D., Knetzger, K. J., Wharton, M. B., McCartney, J. S., Bales, C. W., Henes, S., Samsa, G. P., Otvos, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020194 · Cited by 1,554
Cited by
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Tong, X., Xu, J., Lian, F., Yu, X., Zhao, Y., Xu, L., Zhang, M., Zhao, X., Shen, J., Wu, S., et al. (2018) · mBio · doi:10.1128/mbio.02392-17 · Cited by 378
Nutraceuticals and dyslipidaemia: Beyond the common therapeutics
Scicchitano, P., Cameli, M., Maiello, M., Modesti, P. A., Muiesan, M. L., Novo, S., Palmiero, P., Saba, P. S., Pedrinelli, R., & Ciccone, M. M. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2013.12.006 · Cited by 350
Metadata
- Authors
- Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J.
- Affiliations
- Chestnut Hill Hospital (US)
- Corresponding author
- Becker, David J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2009-06-16
- Volume
- 150
- Issue
- 12
- Pages
- 830-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2029932977
- Cited by
- 275
- References
- 49
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 6 · 2023: 11 · 2022: 6 · 2021: 5 · 2020: 8 · 2019: 17 · 2018: 17 · 2017: 19 · 2016: 17 · 2015: 25 · 2014: 24 · 2013: 24 · 2012: 22
- FWCI
- 28.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Complementary and Integrative Health (T32AT000600)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Natural Products and Biological Research
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- red yeast rice, dyslipidemia, statin intolerance, LDL cholesterol lowering, therapeutic lifestyle changes, herbal supplements, myalgia, creatine kinase, liver enzymes, hypercholesterolemia, Brief Pain Inventory, weight loss, triglycerides, HDL cholesterol, total cholesterol, lipid-lowering therapy, statin adverse effects
- MeSH terms
- Aged, Biological Products, Cholesterol, Creatine Kinase, Female, Humans, Hypercholesterolemia, Life Style, Cholesterol, LDL, Liver, Male, Middle Aged, Muscular Diseases, Pain, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dietary Supplements, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-150-12-200906160-00006
- The paper
- Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009). Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-150-12-200906160-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.